Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

Pfizer’s key oncology drugs are Ibrance, Xtandi, Lorbrena, Braftovi/Mektovi, as well as antibody-drug conjugates or ADCs ...

Let us delve deeper to understand whether to buy, sell or hold Pfizer stock. PFE’s Price Performance & Valuation So far this year, Pfizer’s stock has declined 13.7% compared with a decrease of ...

Pfizer's (PFE-0.28%) management team is confident in its 2025 opportunities. *Stock prices used were the afternoon prices of May 20, 2025. The video was published on May 22, 2025.

Pfizer's (NYSE: PFE) share price has fallen more than the S&P 500 so far this year. If you're a growth investor, you probably won't be interested in buying Pfizer stock. Pfizer's top-selling ...

On Tuesday, investors continued to snap up shares of big pharmaceutical company Pfizer (NYSE: PFE). On Tuesday, Pfizer's stock closed the day 1.5% higher, providing a pleasant contrast to the S&P ...